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ABSTRACT
Haploidentical hematopoietic stem cell transplantation (HSCT) provides an opportunity for nearly all patients
to benefit from HSCT when a human leukocyte antigen (HLA) genotypically matched sibling is not available.
Initial results with the use of mismatched allografts led to limited enthusiasm because of graft-versus-host
disease (GVHD) and infectious complications, resulting in an unacceptable treatment-related morbidity and
mortality. Recent advances with effective T cell depletion, the use of a “megadose” of stem cells, earlier
detection of severe infections, combined with better antimicrobial therapy and reduced-intensity conditioning
(RIC) has significantly decreased the early transplant-related mortality and GVHD, whereas enabling prompt
engraftment, hence advancing the therapeutic benefit of haploidentical transplantation. However, the cardinal
problems related to delayed immune reconstitution allowing posttransplant infectious complications and
relapse remain, limiting the efficacy of haploidentical HSCT. Preliminary data has demonstrated the potential
for use of adoptive cellular immunity and selective allodepletion in rapidly reconstituting immunity without
GVHD. The encouraging reports from haploidentical transplant using noninherited maternal antigen
(NIMA)-mismatched or natural killer (NK) alloreactive donors may greatly increase the donor availability and
open the way to more appropriate donor selection in HLA-haploidentical HSCT. Future challenges remain in
determining the safest approach for haploidentical transplant to be performed with minimal risk of GVHD,
whereas preserving effective graft-versus-leukemia activity and promoting prompt immune reconstitution.
© 2007 American Society for Blood and Marrow Transplantation
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lNTRODUCTION
Allogeneic hematopoietic stem cell transplantation
HSCT) has been successfully used to treat many high-
isk hematologic malignancies and marrow failure syn-
romes. The best results with allogeneic HSCT have
een obtained in patients receiving an allograft from a
uman leukocyte antigen (HLA) matched sibling. As the
hance of ﬁnding an HLA genotypically identical sibling
onor is only 25%, much attention has been focused on
he use of alternative donors, either from unrelated vol-
nteer adult donors, umbilical cord blood (UCB), or
artially matched related donors. Despite the expansion
f worldwide unrelated donor registries that have
arkedly improved the chances of ﬁnding a donor for
any patients [1], the application of transplantation rsing unrelated adult volunteer donors remains lim-
ted by some major obstacles, including: (1) the
ariable chance of ﬁnding a suitably genotypically
atched unrelated donor, from 60%-70% for Cau-
asians to under 10% for ethnic minorities [2,3]; the
umbersome process of identifying, typing, and har-
esting an unrelated donor translating to the median
ime interval between initiation of a search and the
onation of marrow of about 4 months [4], render-
ng this option less viable for patients who urgently
eed transplantation. Many such patients do not
aintain a remission or survive the long waiting
eriod until a donation is available. Moreover, ab-
ative allogeneic transplant using a matched unre-
ated donor is still associated with a high transplant-
elated mortality (TRM) (30%-40%) and high
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L.-P. KOH et al.1250ong-term morbidity [5-9]. UCB donations, on the
ther hand, overcome some of these limitations be-
ause of easy procurement, the absence of risk for
onors, potential reduced risk of graft-versus-host dis-
ase (GVHD) [10], and less stringent criteria for HLA
atching for donor-recipient selection. However, en-
raftment remains a signiﬁcant concern, in part from
he low number of progenitor cells contained in a
ingle UCB unit. Delayed neutrophil recovery and
RM remain the main obstacles for successful UCB
ransplantation, particularly in patients receiving a
yeloablative preparative regimen [11,12].
The use of hematopoietic stem cells (HSC) from
elatives who are only partially HLA matched pro-
ides some advantages for patients lacking fully HLA-
atched sibling or unrelated donors. Virtually all pa-
ients have at least 1 HLA-partially matched parent,
ibling, or child, who is immediately available to serve
s a donor. Further, the immediate availability of this
ismatched family member could have important
reatment implications as patients will not be lost to
arly relapse, and ﬁnancial implications as the consid-
rable expenditure of additional typing and procure-
ent of unrelated donor graft can be avoided.
PPROACHES USING ABLATIVE THERAPIES (TABLE 1)
arly Studies Using T Cell Replete Marrow Grafts
The results of the haploidentical transplant in
arly series reported in the early 1990s were largely
isappointing, mainly because of the high incidence of
ortality from the T cell-mediated alloreactions in
he graft-versus-host (GVH) directions, which caused
ethal GVHD and in the host-versus-graft (HVG)
irection, which caused graft rejection [13,14]. In con-
rast, the results in patients receiving transplant from
aploidentical family members for severe combined
mmunodeﬁciency (SCID) were more encouraging.
linical studies have demonstrated that extensive ex
ivo T cell depletion (TCD) of bone marrow to a
aximum residual of 2-4  104 T cells/kg body
eight infused to the patient prevents acute and
hronic GVHD (aGVHD, cGVHD) without any
ther posttransplant immunosuppressive prophylaxis
15]. Unfortunately, when tested in leukemic patients,
aploidentical T cell-depleted bone marrow trans-
lantation was associated with a high incidence of
raft rejection because the balance between recipient
nd donor T cells shifted in favor of the unopposed
VG reaction.
In 1 of the earliest and largest reports on the use of
ismatched related donor transplant, investigators from
red Hutchinson Cancer Research Center clearly illus-
rated that haploidentical transplant is associated with a
igher incidence of GVHD, delayed engraftment, and
raft failure [16,17]. In patients whose posttransplant pmmunosuppression consisted of methotrexate (MTX)
lone, the risk of aGVHD was signiﬁcantly increased in
atients receiving marrow grafts from donors incompat-
ble from 1, 2, or 3 HLA loci. Patients receiving mar-
ow grafts from HLA-incompatible marrow donors
ad a relative risk for GVHD of 3.23 compared with
ontrols. Notably, the study showed that the use re-
ated marrow with no more than a single HLA-A, B,
r -DR mismatch provided clinical results comparable
o 6 of 6 HLA genotypically identical sibling HSCT.
owever, the outcome of 2 or 3 loci-mismatched
ransplantation without graft manipulation remains
oor [16]. Subsequent studies of patients whose post-
ransplant immunosuppression consisted of cyclospor-
ne (CSP) and MTX also showed that the degree of
verall HLA incompatibility is inversely correlated
ith the probability of survival, suggesting that the
eleterious effect of GVHD remains prohibitive for
hese groups of patients.
Powles et al. [18] reported the outcome of 35
atients with acute leukemia receiving a 1-3 HLA
ismatched marrow graft from parent, child, or sib-
ing, following cyclophosphamide/total body irradia-
ion (TBI) or cyclophosphamide/melphalan condi-
ioning. Graft failure was seen in 29% of patients, and
VHD occurred in 80% of patients, with only 1
eath as a direct consequence of GVHD. Fatal com-
lications, likely immune-mediated, consisted of acute
ulmonary edema, convulsions, intravascular hemoly-
is, and renal failure, and were noted in 12 of the 35
atients. The high mortality rate associated with this
pproach, with nonrelapse death occurring in more
han half of the patients, further highlighted the in-
erent difﬁculties of haploidentical transplantation,
hus limiting its applicability to many patients requir-
ng the transplant.
Another analysis reviewed 2000 patients reported
o the International Bone Marrow Transplant Regis-
ry (IBMTR) [19] showed that TRM was signiﬁcantly
igher after alternative donor transplant compared to
of 6 HLA-matched sibling transplants. Patients with
arly leukemia receiving an HLA matched sibling
ransplant had the lowest risk of treatment failure and
RM compared with those receiving a 1-2 HLA mis-
atched related or unrelated transplant. However, the
ifference in outcome became less striking in patients
ith advanced leukemia. In this group, treatment fail-
re after 1 HLA-antigen mismatched related donor
ransplant was similar to 6 of 6 HLA matched sibling
ransplants, and the risk of other alternative donors
as increased approximately 50%. This is primarily
xplained by the higher treatment relapse rate in HLA
atched sibling transplants for advanced disease. Sim-
lar results have been demonstrated by another data-
ase analysis reported by the Japanese Society for
ematopoietic Cell Transplantation, in which the im-
act of HLA mismatch on survival was smaller in
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Haploidentical or Mismatched Transplant 1251atients with high-risk disease compared to standard-
isk disease [20].
ecent Studies Using T Cell Replete
ematopoietic Cell Grafts
Lu et al. [21] from Beijing, China, retrospectively
ompared a large cohort of patients who received
yeloablative transplant from either matched sibling
onors or mismatched/haploidentical family donors.
lthough the transplant procedure involved the use of
nmanipulated hematopoietic donor grafts, the inclu-
ion of ATG in the conditioning for the mismatched/
aploidentical transplants, which is known to persist
n the plasma for several days, effectively provides in
ivo donor T cell depletion. All patients were given
SP, mycophenolate mofetil (MMF), and methotrex-
te (MTX) as GVHD prophylaxis. There were more
atients in the mismatched/haploidentical transplant co-
ort who received combined granulocyte-colony stimu-
ating factor (G-CSF)-mobilized marrow (G-BM) and
eripheral blood stem cell (PBSC) (G-PB) graft. Nota-
ly, this comparison study showed that every endpoint
n terms of relapse (13% versus 18%), TRM (14%
ersus 22%), overall (OS 72% versus 71%), and leu-
emia-free survival (71% versus 64%) between the
LA-matched and mismatched HSCT did not statis-
ically differ, although trended in favor of the matched
roup. The relatively low incidence of grade III-IV
GVHD (11%) among the mismatched cohort in this
tudy was impressive. These ﬁndings may be related to
1) the use of ATG providing in vivo depletion of
ecipient T cell favoring engraftment, but also deple-
ion of donor T cells reducing aGVHD and cGVHD;
2) possible effect of combination of CSP, MTX, and
MF as postgrafting immunosuppression; (3) the im-
unomodulatory effect of T-polarized cells (Th2)
nd mesenchymal stem cells (MSCs)/mesenchymal
stroma) progenitor cells (MPCs) from the G-CSF
obilized marrow graft and PBSC, respectively.
It becomes clear from these early clinical reports
hat haploidentical or partially matched HSCT with T
ell-replete marrow grafts following myeloablative
onditioning was associated with high TRM from
VHD, graft failure, delayed immune reconstitution,
ulnerability to life-threatening infections, and re-
apse. Thus, haploidentical transplant could not be
idely adopted as a routine procedure, leading to
ubsequent efforts focusing on strategies to overcome
hese barriers, which include: (1) reducing the inten-
ity of conditioning (RIC) and hence ameliorating the
egimen-related toxicity, (2) promoting engraftment
apacity of the graft by using G-CSF-mobilized PBSC
nd the use of megadose of stem cells, (3) effective T
ell depletion methods to decrease both graft rejection
nd GVHD by different in vivo  ex vivo T cell deple-
ion procedures, (4) exploiting the concept of alloreactive vK cells, which may play a vital role in facilitating
ngraftment and in preventing relapse [22].
The initial attempts in overcoming HLA barrier
ocused mainly on strategies for effective host and
raft T cell depletion. However, the beneﬁt of a de-
rease in GVHD from donor TCD was offset by a
igher incidence of graft rejection, relapse, and infec-
ion [14,23]. Another major step toward induction of
olerance was achieved following the pioneering work
y Reisner [24] and the clinical results by Aversa et al.
25] using “megadoses” of hematopoietic stem cells
obilized into the peripheral blood by growth-factor
se as a supplement to the heavily T cell-depleted
ismatched bone marrow stem cells. A remarkably
igh 95% engraftment rate was seen in patients re-
eiving an allograft from haploidentical 3 of 6 HLA-
atched family members in the absence of severe
VHD despite no postgrafting immunosuppression
25]. The encouraging results of their subsequent re-
ort using strategies involving large doses of TCD
lood-derived stem cells spurred further interest in
xploring the option of using haploidentical/mis-
atched related donors for patients who may beneﬁt
rom a transplant but do not have a readily available
atched donor.
Since the 1990s, several investigators have ap-
roached haploidentical transplantation by using
artial TCD combined with intensive immunosup-
ression. In single institution studies, grade II-IV
VHD incidence has ranged from 18% to 40% in
ecipients of HLA-mismatched marrow after TCD
sing anti-CD6 or T10B9 monoclonal antibodies
mAb) for purging [26-28]. Henslee-Downey et al.
28] were among the early pioneers in exploiting a
ovel sequential immunomodulation pre- and post-
ransplant using ex vivo TCD with the T10B9 mono-
lonal antibody and in vivo T cell lysis with immuno-
oxin H65-RTA, following intensive total body
rradiation (TBI)-based myeloablative conditioning.
eventy-two patients received allografts from hap-
oidentical family members using this treatment pro-
ocol. The 88% engraftment rate, 16% probability of
rade II-IV aGVHD, and 51% probability of exten-
ive cGVHD were encouraging. At a median fol-
ow-up of 21.5 months, the 2-year disease free survival
DFS) was 31%, with 53% probability of DFS seen
mong standard risk patients. The study highlighted
he efﬁcacy of partial TCD in preventing GVHD in
ismatched transplantation and the potential of post-
rafting immunomodulation in lowering the risk of
raft failure.
In a recent report from the same institution,
ehta et al. [29] reported the outcome of 201 patients
ith acute leukemia who underwent transplantation
rom partially mismatched related donors between
993 to 1999, using bone marrow grafts that were ex
ivo TCD with T10B9 (1993-1994) or OKT3 (1995-
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L.-P. KOH et al.1252able I. Myeloablative Mismatched/Haploidentical Stem Cell Transplantation
Institutions
(Authors,
year) Diagnosis No of Patients
Adults/
Children
Median Cell
dose (106/kg)
CD34/CD3
Preparative
Regimens
GVHD
Prophylaxis
Method of T cell
depletion
oyal Marsden
(Powles et
al, 1983)[18]
AML, ALL 35 Both N.S. Cy/TBI or Cy/Mel CSP / MTX None
BMTR
(Szydlo et
al, 1997)
[19]
CML, Acute
leukemia
Mismatched
related
(N330)
Mismatched
unrelated
(N108)
Both N.S. TBI/Cy
TBI/Cy/Others
TBI/Others
CSP / MTX/
Others
*TCD
N.S.
ilwaukee
(Drobyski et
al, 2002)[30]
Leukemia,
lymphoma,
MDS
Mismatched
unrelated
(N58)
Hapolidentical
(N48)
Both 1.6/N.S. TBI/Cy/AraC/MP TCD Ex vivo TCD
with T10B9 or
OKT3
SHCT (Kanda
et al, 2003)
[20]
Leukemia,
MDS
142 Adults N.S. TBI/Cy
Bu/Cy
CSP/MTX (87%)
Others (13%)
N.S.
SC (Mehta
et al, 2004)
[29]
AML, ALL 201 Both 1.9/5 TBI/VP16/AraC/
Cy/ATG
CSP, partial
TCD, MP,
ATG
Ex vivo TCD
with T10B9 or
OKT3
eijing, China
(Lu et al,
2006)[21]
Leukemia,
MDS
135 Both 2.3/177 Bu/Cy/AraC/
MeCCNU/ATG
CSP/MTX/MMF In vitro TCD
with ATG
erugia
(Aversa et
al, 2005)[43]
ALL, AML 104 Both 13.8/0.01 TBI/TT/Flu/ATG TCD Ex vivo CD 34
selection 
negative
selection with
Anti-CD2
mAb
uebingen
(Lang et al,
2004)[44]
MHD, NMD 63 Children 19.5/0.011 TBI or Bu-based
with Flu/TT/
ATG/Cy added
TCD Ex vivo CD 34 or
CD133
selection
apan
Multicenter
Study (Kato
et al, 2000)
[45]
MHD, NMD 135 Both 3.2/0.06 (BM)
5.5/0.09
(PBSC)
4.9/0.01
(BM
PBSC)
TBI based regimen
in majority of
patients
CSP/FK506/
MTX/Steroids
TCD[*]
Ex vivo CD 34
selection
anadian
Multicenter
Study
(Walker et
al, 2004)[46]
AML 11 Adults 13.72/0.0049 Mel/TT/Flu/ATG TCD Ex vivo CD 34
selection
VHD, graft-versus-host disease; NRM, non-relapse mortality; USC, University of South Carolina; IBMTR, International Bone Marrow
Transplant Registry; JSHCT, Japan Society for Hematopoietic Cell Transplantation; CML, chronic myelogenous leukemia; AML, acute
myelogenous leukemia; ALL, acute lymphoblastic leukemia; MDS, myelodysplastic syndrome; AraC, cytarabine; MP, methylprednisolone;
TBI, total body irradiation; Cy, cyclophosphamide; Bu, busulphan; TT, thiotepa; Flu, ﬂudarabine; Mel, Melphalan; LFS, leukemia-free
survival; OS, overall survival; VP16, etoposide; MeCCNU, methyl-CCNU;ATG, antithymocyte globulin; DFS, disease free survival; EFS,
event-free survival; TCD, T cell deletion; CSP, cyclosporin; N.S., not stated; MTX, methotrexate; MMF, mycophenolate mofetil; MHD,
malignant hematological disease; NMD, non-malignant disease.; BM, bone marrow; PBSC, peripheral blood stem cell.
T cell depletion in some patients.
Refers to patients with primary graft rejection after ﬁrst transplantation.
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Primary Graft
Failure Acute GVHD NRM Outcome/Survival Remarks
29% 80% 57% 31% at 6 months-3 years
ismatched related:
9%-16%
ismatched
unrelated: 9%
Gd II-IV: Mismatched
related: 44%-56%
Mismatched
unrelated: 63%
Gd III-IV: Mismatched
related 27-36%
Mismatched
unrelated: 47%
Mismatched related:
53%-67%
Mismatched
unrelated: 69-79%
Mismatched related:
15%-36% LFS
Mismatched unrelated:
17%-26% LFS
1) Higher treatment failure in
alternate donor transplant.
2) Better outcome in matched
sibling transplant than 1-2
Ag mismatched
related/unrelated transplant
for early leukemia
3) Similar outcome in advance
leukemia.
ismatched
unrelated (N3)
apoidentical
(N2)
Mismatched
unrelated: Gd II-IV:
33%
Hapoldentical: Gd
II-IV: 46%>
Mismatched
unrelated: 45%
Hapoidentical: 42%
2 year OS: Mismatched
unrelated: 34%
Hapolidentical: 21%
2 year DFS: Mismatched
unrelated: 29%
Hapolidentical: 17%
Overall survival significantly
higher after HLA-matched
unrelated donor transplant
compared with the other
two groups.
6.3% Gd III-IV: 30% in 1
locus mismatch
NA N.S. Impact of HLA mismatch on
survival was smaller in
patients with high-risk
disease as compared to
standard-risk disease.
2% Gd II-IV: 13%
Gd III-IV: 15%
51% 5 year OS: 19%
5 year DFS: 18%
0% Gd II-IV: 40%
Gd III-IV: 16%
22% 2 year OS: 71%
2 year LFS: 64%
7% Gd II-IV: 8% 40% 5 year EFS: 47% (for
patients in remission at
transplant)
Disease status had strong
impact on survival
17% Gd II: 7% 29% 3 year DFS: 48% (for ALL/
NHL in remission)
13% Gd II-IV: 21% 47% 5 year DFS:
39% (standard risk
patients)
5% (high risk patients)
0% 0% 55% 9 months DFS: 9%, OS: 9%
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L.-P. KOH et al.1254999) mAb. GVHD prophylaxis consisted of CSP,
ethylprednisolone, and ATG. The median T cell
ose in the marrow was 5  104/kg. Using an inten-
ive ablative TBI-based conditioning regimen, the
ransplant resulted in an overall engraftment rate of
8%. The cumulative incidence of grade II-IV
GVHD and cGVHD were 13% and 15%, respec-
ively. The 5-year cumulative incidence of relapse and
RM were 31% and 51%, respectively. The 5-year
S and DFS were 19% and 18%, respectively. In the
ultivariate analysis, younger patients with disease in
emission receiving allograft from a less HLA-dispar-
te donor had the best outcome, emphasizing the
mportance of patient selection and pretransplant dis-
ase status in determining the outcome of this high-
isk procedure.
Drobyski et al. [31], in a single institution analysis,
ompared the outcome of patients who received trans-
lant from a matched unrelated donor, mismatched
nrelated donor, or haploidentical donor. All patients
ad received a TCD marrow graft, using either T10B9
r OKT3. There was a decrease in relapse and in-
rease in survival in matched unrelated donor recipi-
nts compared with the other 2 groups, but the degree
f TCD might not have been sufﬁcient for the hap-
oidentical setting. The higher TRM after transplan-
ation from a mismatched unrelated or haploidentical-
elated donor transplant compared to matched
nrelated donor transplant demonstrated a clear effect
f HLA disparity.
arly Studies Using TCD Hematopoietic Cell
rafts via CD34 Selection
An important landmark in the development of
aploidentical transplant came with the concept of
sing “mega” doses of stem cells, which was demon-
trated to overcome the major histocompatibility
omplex (MHC) barrier, presumably by generation of
veto effect” by the stem cells [24,31]. With these
dvances also came the realization that natural (NK)
ells from HLA-mismatched donors can exert an an-
ileukemia effect against a patient’s blasts in the ab-
ence of HLA-antigenic engaging killer-inhibitory re-
eptors (KIR). Aversa et al. [32], from the University
f Perugia, Italy, pioneered the “megadose” approach
y infusing G-CSF mobilized peripheral blood and
one marrow stem cells, both ex vivo depleted of T
ells by soybean agglutination and E-rosetting, fol-
owing an intensive TBI-based conditioning regimen.
lthough engraftment was prompt with low occur-
ence of GVHD, subsequent follow-up showed difﬁ-
ulty with both late rejection and/or graft failure.
hese events resulted in increased TRM in excess of
0%, leading to subsequent modiﬁcation of treatment
rotocols (as discussed below) [33].
This approach was combined with another im-
ortant breakthrough in the ﬁeld of haploidentical oransplantation: the development of a powerful
ethod to eliminate T cells via selection columns.
irst introduced by investigators from Tuebingen, the
vailability of CD34-enrichment technique using the
liniMACS system (Miltenyi Biotec Gmbh, Bergish
ladbach, Germany) has provided a reproducible
CD of 4.5 logs in several studies [34]. This tech-
ology, initially intended to prepare stem cell grafts
or autologous transplantation [31,35,36], was later
xtended to allogeneic transplantation settings
34,37,38,39].
ecent Studies Using T Cell-Depleted
ematopoietic Cell Grafts via CD34 Selection
Results from Perugia, Italy. Following the initial suc-
ess with high incidence of engraftment and low inci-
ence of grade II-IV aGVHD, the Perugia group has
ade modiﬁcations that have resulted in marked im-
rovement in clinical outcome: (1) The transplant pro-
ocol was modiﬁed by substituting cyclophosphamide
ith ﬂudarabine in an attempt to reduce nonhemato-
ogic toxicity. This was based on the observation in the
urine model that ﬂudarabine  TBI provided equiva-
ent immunosuppressive effects and obviates other tox-
cities [40]. In addition, the total lung dose of radiation
as decreased from 6 to 4 Gy. (2) Further depletion of
cells, hence further diminishing GVHD, was
chieved by modiﬁcation in graft processing. Positive
mmunoselection of peripheral blood CD34 cells
as used instead of the soybean agglutination and E
osetting. The initial technique of 1-round E-roset-
ing followed by positive immunoselection of the
D34 cells using the Ceprate-SC system [33] was
ubsequently substituted by the 1-step CD34 cell
election using the Clinimacs device (Miltenyi Biotec)
r 2-step (positive/negative selection-antiCD34/
ntiCD2) procedure using the Isolex instrument. (3)
he use of G-CSF-mobilized peripheral blood pro-
enitor cells (PBPC) instead of bone marrow grafts,
hich facilitates the transplantation of megadoses of
aploidentical cells. (4) The use of G-CSF to promote
ngraftment was eliminated from the protocol since
999, following the observation that it impaired im-
une reconstitution [41,42]. These modiﬁcations
ave resulted in a favorable outcome in a large series
f high-risk acute leukemia, with sustained full donor
ype engraftment in over 95%, rapid hematopoietic
ecovery, and a very low incidence of aGVHD grade
I-IV without the need for any posttransplant immune
uppression as prophylaxis [9,33]. Importantly, the
SC harvesting or mobilization procedure was well
olerated by the donors. In another recent report, [43]
04 patients with high-risk leukemia [67 acute my-
logenous leukemia (AML) and 37 acute lymphoblas-
ic leukemia (ALL)] were transplanted between 1999
nd 2004 following the modiﬁed transplant protocol
f the Perugia group. Engraftment was achieved in
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Haploidentical or Mismatched Transplant 125500 of 101 evaluable patients. The unfortunate high
RM of 40% (mostly from infection) was anticipated,
iven that many of these patients were heavily pre-
reated and had advanced disease status at transplan-
ation (36.5% were in relapse; 10.1% in 3rd or 4th
emission). aGVHD and cGVHD developed in 8%
nd 7% of evaluable patients, respectively. Patients in
ny remission had a remarkable event-free survival of
7%  6%. The cumulative incidence of relapse in
atients transplanted in remission from NK alloreac-
ive donors was 14%, whereas it was 28% in the
onalloreactive donors. For patients transplanted in
elapse, the corresponding relapse rates were 33% and
5%, respectively, emphasizing the importance of
retransplant disease control and presence of NK al-
oreactivity.
Results from Tuebingen, Germany. Investigators from
uebingen adopted a similar approach as reported
bove for haploidentical HSCT using myeloablative
onditioning and a high-dose CD34 cell-selected
raft. In a recent report, Lang et al. [44] updated their
-year experience in 63 pediatric patients receiving
D34 or CD133 selected stem cell transplant from
aploidentical family donors. G-CSF-mobilized stem
ell were selected by either anti-CD34- or anti-
D133-coated microbeads. Using a myeloablative
onditioning regimen with no postgrafting immuno-
uppression given, primary sustained engraftment oc-
urred in 83% of patients (98% after reconditioning)
nd aGVHD occurred in only 7% of evaluable
atients.
Viral infection was a signiﬁcant cause of mortality
ithin the ﬁrst 6 months posttransplant, suggesting
hat impaired immune recovery remains an important
arrier to success using this TCD myeloablative ap-
roach. Notably, this study resulted in a long-term
urvival rate of 48% for children with ALL in remis-
ion, which compared favorably with the historical
ontrol group, as well as with other pediatric studies
sing unmanipulated bone marrow from matched un-
elated donors.
Results from Multicenter Studies. A nationwide sur-
ey in Japan of the outcome of haploidentical trans-
lants following negative TCD using the Isolex
D34 selection device was reported by Kato et al.
45]. One-hundred thirty-ﬁve patients with various
ematologic diseases were transplanted using myeloa-
lative therapy followed by HLA haploidentical re-
ated donors, of whom 64 patients received grafts with
HLA locus mismatches and 43 patients had 3 loci
ismatched. A majority of the patients were given CSP,
acrolimus, MTX, or corticosteroids, either alone or in
ombination as GVHD prophylaxis. The median
D34 cell dose was lower than that reported by the
erugia group: 3.2  106/kg for patients receiving bone
arrow only, 5.5  106/kg for patients receiving PBSC
nly, and 4.9  106/kg for patients receiving both mar- eow and PBSC. The median CD3 T cell doses were
.0, 9.4, and 12.1 104/kg for the 3 groups, respectively.
he incidence of grade III-IV aGVHD was 8.4%, close
o that observed for transplants from 6 of 6 HLA geno-
ypically matched siblings or from 6 of 6 HLA-matched
nrelated donors without TCD. Graft failure occurred
n 13% of patients, with a higher rate seen in nonmalig-
ant disease (40%) than in hematologic malignancies
13%). DFS at 5 years was 39% in standard-risk patients
nd 5% in high-risk patients. Results of this study sup-
ort the hypothesis that standard doses of CD34 cells
re inadequate for consistent engraftment of HLA hap-
otype mismatched donor cells, and that a moderate
egree of TCD is inadequate to prevent GVHDwithout
ostgrafting immunomodulation.
A similar approach based on a modiﬁed regimen
eveloped by the Perugia group, using CD34 selec-
ion as TCD, was investigated in a Canadian multi-
enter study [46]. Eleven patients with AML in vari-
us stages were accrued. The authors observed
ngraftment in all 11 patients without occurrence of
VHD. However, 10 of the 11 patients died from
elapse or infection. The disappointing results high-
ighted the problems of graft rejection and GVHD as
arriers to haploidentical transplantation can be over-
ome with this approach, but the slow immune recon-
titution limits its general use.
x Vivo Induction of T Cell Anergy
A competing approach not based on megadose
tem cells was evaluated by Guinan et al. [47], in
hich anergy but not TCD was the basis for mis-
atched transplantation. To induce anergy, donor
arrow was harvested and cocultured with irradiated
ononuclear cells from the recipient in the presence
f soluble CTLA-4-Ig. After myeloablative condition-
ng, 12 patients, almost all in advanced status of the
ematologic malignancies, received marrow contain-
ng a median of 2.8  107/kg of CD3 T cells from
he mismatched/haploidentical family that had been
reated to induce anergy. Evaluable patients engrafted
t a median of 20 days (range: 14-23), with full donor
himerism observed in 8 of 10 patients in whom engraft-
ent occurred. Of the 12 patients, 7 died of infections,
ultiorgan failure, hemorrhage, or relapse and 5 were
live and in remission 132 to 863 days after transplanta-
ion. Only 3 patients developed aGVHD conﬁned to the
astrointestinal tract, and no deaths were attributable to
VHD.
PPROACHES USING NON/MYELOABLATIVE
HERAPIES (TABLE 2)
Although the highly immunosuppressive and my-
loablative conditioning regimen and a megadose of
xtensively TCD G-CSF mobilized PBSC cells has
Table II. Nonmyeloablative Mismatched/Haploidentical Stem Cell Transplantation
Institutions
(Authors, years) Diagnosis
No of
Patients
Adults/
Children
Preparative
Regimens
GVHD
Prophylaxis
Median Cell
dose (106/
kg) CD34/
CD3
Method of
T cell
Depletion
Primary
Graft
Failure GVHD NRM
Outcome/
Survival Remarks
Duke University
(Rizzieri,
2007)[65]
Leukemia,
Myeloma
Lymphoma,
MPD
49 Adults Flu/Cy/Campath MMF  CSP 13.5/460 In vivo  ex
vivo TCD
with
Campath
6% Gd III-IV: 16%
Gd III-IV: 8%
10.2% OS 31% @ 1
year
Standard risk
patients:
OS 63% @
1 year
Tuebingen/Dresden
(Bethge,
2006)[55]
Leukemia/
Lymphoma
10 Adults Flu/TT/
Melphalan/OKT3
TCD 7.8/0.02 Ex vivo
CD3/CD19
negative
depletion
with anti-
CD3 and
CD19
mAb
0% Gd II: 60 %
Gd IV: 10%
30% OS: 50% @
>1 year
Tuebingen
(Handgretinger,
2007)[56]
HM/ AA 38 Both Flu/TT/Melphalan TCD 16/0.049 Ex vivo
CD3/CD19
negative
depletion
with anti-
CD3 and
CD19
mAb
17% Gd II-IV: 27% 2.6% EFS: 70% in
good risk
patients
EFS: 20% in
poor risk
patients
Good risk:
Patients
with non-
HM and in
CR
Poor risk:
Patients
with
chemo-
refractory
disease
MGH (Spitzer,
2003)[58-60]
Leukemia/
Lymphoma
12 Adults Cy/Anti-CD2
Mab/Thymic
RT
CsP  ex vivo
TCD PBSC
10.6*/8.9[* Ex vivo CD
34
selection
in vivo
TCD
using
anti-CD 2
mAb
0% Gd II-IV: 17% 25% 17% DFS,
25% OS
@ 15-34
months
John Hopkins
(O’Donnell,
2002)[61]
Leukemia/
MDS
13 Adults TBI/Cy/Flu/Post
BMT Cy
CsP/MMF 5.3/3.2 Not done 31% Gd II-IV: 54% 8% 38% DFS,
46% OS
@ >6
months
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Haploidentical or Mismatched Transplant 1257emonstrated encouraging survival results, it is not
ithout limitations. First, the procedure is associated
ith signiﬁcant regimen-related toxicity and high
RM (between 35% and 40%) [43,44] primarily from
nfections. Second, a megadose of puriﬁed CD34
ells is crucial in overcoming the barrier of residual
ntidonor cytotoxic T-lymphocyte precursors in
CD mismatched transplant. There is continuing
oncern with regard to the slow engraftment or graft
ailure in patients receiving a lower cell dose. Previous
tudies from Tuebingen have shown delayed engraft-
ent at CD34 doses less than 8 106/kg body weight
48]. As such, most physicians would usually target for
egadose of stem cell (10  106 CD34 cells/kg
ody weight) from the donor, whereas planning for
aploidentical transplants. This can place consider-
ble demand on both the donors and the pheresis
ervice for the following reasons: (1) The high graft
ontent is an obstacle in large adults. (2) The long
ours of multiple days of pheresis can be exhausting,
ith a slight increase in pheresis-related adverse ef-
ects to donors. (3) For the pheresis and stem cell
rocessing laboratory staff, the procedures involved
an be time-consuming and labor-intensive. Even
ith high cell doses, graft failure in the range of
%-14% has been reported by some [49-51]. Com-
unication from investigators and reports given at
onferences on haploidentical transplantation have in-
icated that both graft failure and GVHD remained a
roblem, and there were few survivors [52]. Develop-
ng new strategies of TCD or graft manipulation in
ismatched HSCT, with an aim to improve engraft-
ent with better tolerated, less toxic conditioning, has
ecome an important area of research.
Although the number of mismatched allogeneic
SCT has increased steadily over the past few de-
ades, this high-risk ablative procedure can only be
ffered only to a minority of patients, because most
ubjects are beyond the age where myeloablative pre-
arative regimens can be delivered with a reasonable
egree of safety. GVHD, TRM, and other toxicities
emain signiﬁcant deterrents and have limited use in
therwise healthy, younger patients as well. To extend
llogeneic HSCT to older patients with comorbidi-
ies, RIC or nonmyeloablative conditioning lacking
igniﬁcant regimen-related toxicities have been devel-
ped.
Results from Tuebingen/Dresden. Based on the
romising experiences gained at St. Jude Children’s
esearch Hospital (SJCRH), Memphis, in the pediat-
ic population [53,54], investigators from Tuebingen
xplored a new TCD strategy in adult patients follow-
ng dose-reduced conditioning [55]. Using this new
pproach, T and B cells (CD3/CD19) are negatively
epleted from PBSC with 3.5-4 log TCD using anti-
D3- and anti-CD19-coated microbeads on a Clini-MACS device. In contrast to the CD34 selectionTa (A O
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L.-P. KOH et al.1258trategy pioneered by the Perugia group, CD3/CD19-
epleted grafts harvested using this strategy not only
ontain CD34 stem cells but also CD34 progenitors
nd NK, dendritic, and graft-facilitating cells. Dose-
educed conditioning consisting of ﬂudarabine (150-
00 mg/m2), thiotepa (10 mg/kg), melphalan (120
g/m2), and OKT-3 (5 mg/day, day 5 to 14) was
sed. Ten adult patients with a median age of 43, and
dvanced hematologic malignancies received mis-
atched transplant using this approach. Rapid en-
raftment with full donor chimerism was seen after 2
eeks in all patients. Six patients developed grade II
VHD and 1 developed lethal grade IV GVHD.
RM was 30% and OS was 50%, with 4 patients in
omplete remission with a median follow of 1 year.
he fast engraftment seen in this CD3/CD19 group
ith CD34 doses as low as 5.2  106 CD34 cells/kg
emonstrates that successful haploidentical transplant
ay be feasible even without megadoses of CD34
tem cells. Importantly, the favorable immune recon-
titution with fast reconstitution of NK cells was
oted with this approach, resulting in few infectious
omplications.
In another recent study from Tuebingen, Hand-
retinger et al. [56] reported the outcome of 38 pedi-
tric patients with high-risk hematologic malignancies
nd severe aplastic anemia (AA) receiving haploiden-
ical transplant using this approach. The dose-reduced
onditioning was modiﬁed to a lower dose of ﬂudara-
ine (to reduce neurotoxicity) and OKT3 was
mitted. Primary sustained engraftment occurred in
3% of patients and ﬁnal engraftment was 98% when
he remaining patients with graft failure had a repeat
ransplant. Grade II-IV aGVHD occurred in only
7% of patients. Overall TRM was low at 2.6%. The
avorable event free survival of 70% seen only in patients
ith nonmalignant disease and those in remission at time
f transplant, suggests that disease relapse is a major
bstacle among patients with refractory malignancies
ndergoing haploidentical transplant.
Results from Massachusetts General Hospital. Based
n murine models established by Sykes and colleagues
57], a series of haploidentical stem cell transplanta-
ion have been conducted at Massachusetts General
ospital. To address the problems of graft failure and
VHD, the initial regimen has been modiﬁed to its
urrent form which includes cyclophosphamide, ﬂu-
arabine, MEDI-507 (a monoclonal anti-CD2 anti-
ody) and thymic irradiation. Mixed “split lineage”
ymphohaematopoietic chimerism has been achieved
n most cases with this strategy, with a predominance
f donor myeloid chimerism and a much lower per-
entage of donor T cell chimerism. In addition, mixed
himerism, including the low percentage of donor T
ell chimerism, can be successfully converted to full or
early full donor chimerism with either no GVHD or
anageable, primarily cutaneous GVHD. Recurrent malignancies and late infections have been the chief
easons for treatment failure with this approach. Ef-
orts are underway to optimize the ex vivo TCD of the
roduct and to explore different doses of delayed DLI
58-60].
Results from John Hopkins University. O’Donnell et
l. [63], from John Hopkins University, have per-
ormed nonmyeloablative haploidentical transplant on
3 patients with hematologic malignancies using low-
ose TBI 2 Gy and ﬂudarabine (with or without cy-
lophosphamide) as conditioning. High-dose post-
ransplant cyclophosphamide, given at 50 mg/kg on
ay 3, was added onto tacrolimus/mycophenolate
ofetil (MMF) to improve GVHD prophylaxis. The
edian time to absolute neutrophil count500/L in
patients with engraftment was 15 days (range, 13-16
ays). aGVHD developed in 6 of the 13 patients. Six
f the 13 patients were alive, 5 who were in a complete
emission at a median of 191 days posttransplant,
ncluding 2 patients with graft rejection. The results
uggest possible beneﬁts of pre- and posttransplanta-
ion cyclophosphamide in promoting engraftment and
revention of GVHD.
Results from Osaka University Hospital, Japan.
gawa et al. [62], from Osaka University Hospital
n Japan, investigated the use of ATG-based non-
yeloablative conditioning regimen as previously
eported by Slavin et al. [63], in the haploidentical
ransplant of 26 patients who had hematologic ma-
ignancies in an advanced stage or with a poor
rognosis. Using a conditioning consisting of ﬂudara-
ine, busulfan, and anti-T-lymphocyte globulin and
VHD prophylaxis consisting of tacrolimus and
ethylprednisolone (1 mg/kg/day), 26 patients under-
ent transplantation using PBSC from an 2-3 antigen
LA mismatched donors. All patients except for 1
chieved donor-type engraftment. Full donor chimer-
sm was achieved by day 14. Only 5 (25%) of 20
valuable patients developed grade II GVHD. Sixteen
f the 26 patients are alive in complete remission.
our died of transplantation-related causes, and 6 died
f progressive disease. The event-free survival at 3
ears was 55%.
Results from Tokyo University, Japan. Kanda et al.
64] evaluated the feasibility of haploidentical unma-
ipulated PBSC transplantation from 2 or 3 loci-
ismatched family member using in vivo alemtu-
umab in 12 patients (median age 49.5 years) with
igh-risk hematologic malignancies. Six patients re-
eived a TBI-based myeloablative regimen, whereas
he remaining 6 patients older than 50 years received
ess intensive or nonmyeloablative ﬂudarabine-based
onditioning. Alemtuzumab was added on days 8 to
3 and CSP  MTX were used as GVHD prophy-
axis. There was no graft rejection, and the incidence
f grade III-IV aGVHDwas only 9%. The nonrelapse
ortality (NRM) was observed in only 2 of 12 pa-
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Haploidentical or Mismatched Transplant 1259ients. None of the patients died of infectious causes
espite impaired T cells immune reconstitution dur-
ng the ﬁrst 2 months after transplantation.
Results from Duke University. Rizzieri et al. [65] from
uke University recently reported one of the largest
eries of adult patients with nonmyeloablative transplant
sing 3-5 of 6 HLA-matched family donors. Forty-nine
atients with hematologic malignancies or marrow fail-
re were accrued. The patients in this group were, in
verage, older (median age of 48) than most other
eported series haploidentical transplantation. Using a
onmyeloablative preparative regimen consisting of
udarabine and cyclophosphamide in combination
ith alemtuzumab for in vivo and in vitro TCD, the
roup reported successful engraftment in 94% of pa-
ients, low TRM rates of 10.2% and severe GVHD of
%. With more than half of patients not in ﬁrst CR at
ransplantation, the high CR rate of 75% was encour-
ging. With 4.25 years of median follow-up, 1-year
S in this high-risk group was 31%. Subgroup anal-
sis of 19 standard risk patients showed 63% 1-year
S and 3-year median survival, which compared fa-
orably to reports using alternative matched unrelated
onors or cord blood. Despite the use of TCD regi-
en, immune reconstitution analysis demonstrated
ncouraging evidence of quantitative lymphocyte re-
overy through expansion of transplanted T cells by 3
o 6 months.
The heterogeneous results reported in the litera-
ure is likely a result of a composite of diverse regi-
ens and protocols been employed by different treat-
ent centers. The difference in TRM among various
reatment centers is also likely a result of patient
election, TCD methodology, conditioning regimen
sed, supportive care guidelines, and experience in
ransplanting physicians.
ENEFITS IN IMMUNE RECOVERY FROM USAGE OF
LA MISMATCHED DONORS
ffects of NK Cell/KIR Ligand on Outcome of
aploidentical Transplant
The translation of NK cell recognition of missing-
elf into clinical practice of haploidentical transplant
as opened innovative perspectives in the cure of leu-
emia. Donor-derived NK cells have the potential to
romote engraftment, suppress GVHD, and promote
VT, whereas host-derived NK cells can mediate
raft rejection and affect GVHD by eliminating donor
SCs or activated T cells, respectively. NK cells are
egatively regulated by MHC class I-speciﬁc alleles
66]. Lack of expression of self-MHC molecules on
ismatched allogeneic targets results in susceptibility
o NK cell-mediated lysis (“missing-self” recognition).
n humans, inhibitory cell killer immunoglobulin (Ig)
eceptors (KIRs) recognize groups of HLA-C and cLA-B molecules (KIR ligands). Consequently, when
aced with KIR ligand-mismatched allogeneic targets,
IR-bearing NK cells sense the missing expression of
elf-class I alleles and mediate cell killing.
The important role of alloreactive NK cells in the
etting of haploidentical transplant has been previ-
usly demonstrated. Extensive TCD to prevent
VHD in the setting of haploidentical transplant
llows rapid regeneration of NK cells in the graft.
uggeri et al. [67] have shown that NK alloreactiv-
ty reduced the risk of leukemia relapse in 57
ML patients receiving haploidentical transplant,
hereas improving engraftment and protecting
gainst GVHD. In a recent updated analysis of 112
dult high-risk AML patients who have received hap-
oidentical transplant from 1993 to 2006 [68], the
erugia investigators demonstrated that transplanta-
ion from NK alloreactive donors does not cause
VHD and helps to control leukemia relapse in pa-
ients who are transplanted in remission. The marked
raft versus-leukemia (GVL) effect has translated into
marked survival advantage [65% event-free survival
n patients in any complete remission (CR)]. Although
uch positive effects of a KIR ligand-mismatched hap-
oidentical transplant is only seen in AML for adults in
he Perugia study, similar beneﬁts with lower risk of
elapse was also observed in a study in St. Jude’s
hildren Research Hospital among pediatric patients
ith acute lymphocytic leukemia (ALL) who had re-
eived transplant from haploidentical NK-alloreactive
onor [69,70]. Several groups of investigators subse-
uently tested the KIR ligand incompatibility model
n patients given grafts from HLA-mismatched unre-
ated donors [71-74]. Two studies found lower risks of
elapse in patients with KIR ligand incompatibility in
he GVH direction [71,74], although 2 others did not
nd such association [72,73]. The heterogeneous re-
ults are likely attributable to other factors, such as the
xtent of donor TCD [75], the speed at which NK
ells recover, and/or the use of posttransplant immune
odulation. These data point to the need for further
tudy under different transplant procedures and con-
itions. Nevertheless, the recently demonstrated ben-
ﬁts of NK alloreactivity are expected to encourage
reater use of haploidentical transplantation in the
uture.
In patients with advanced or refractory malignan-
ies, the alloreactivity of NK cells has been exploited
s a form of adoptive immunotherapy, providing a
otential role as an adjunct to HSC transplant. Miller
t al. [76] recently demonstrated the safety and poten-
ial beneﬁt of adoptive haploidentical-related NK cell
herapy without HSCT following high-dose intensity
onditioning. All NK cell donors were haploidentical
amily members; few were KIR-ligand-mismatched in
he GVH direction. Twenty-six percent of a small
ohort of poor-prognosis patients with AML achieved
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L.-P. KOH et al.1260omplete hematologic remission of their leukemia.
ntriguingly, a signiﬁcantly higher complete remission
ate was observed when KIR-mismatched donors were
sed. The study also demonstrated in vivo expansion
f donor-derived NK cells in the majority of the
reated patients, in association with increased levels of
ndogenous IL-15. More importantly, donor NK-cell
nfusions were well tolerated without evidence for
nduction of GVHD. These ﬁndings suggest that hap-
oidentical NK cells can persist and expand in vivo,
nd may have a role in the treatment of selected
alignancies when used alone or in association with
SCT. Additional studies are needed to determine
ow best to exploit the potential beneﬁt of NK cells in
llogeneic HSCT by promoting their recovery with
ytokines such as IL-15 or by selection of speciﬁc
ubsets.
The positive impact of donor versus recipient NK
lloreactivity in the haploidentical transplant studies
as important implications for donor selection. Rug-
eri et al. [68,77] proposed that when it is incorpo-
ated as a criteria for donor selection, the random
3% chance of ﬁnding an NK-alloreactive donor in-
reases to 49%, which approaches the maximum, be-
ause 1/3 of the population expresses all three class I
lleles and are resistant to alloreactive NK killing. The
ear 50% chance of ﬁnding NK-alloreactive donors
ompares favorably with the odds of ﬁnding an unre-
ated donor and has the advantage of no delay between
ecision making and transplant as haploidentical do-
ors are immediately available.
ffects of Nonfetal Maternal Antigen on Outcome
f Haploidentical Transplant
The potential beneﬁt of feto-maternal immuno-
ogic tolerance in allogeneic HSCT was recently dem-
nstrated [78-81], and may serve as a new parameter
n selection of donors. Based on the results of a na-
ionwide HSCT survey conducted in Japan [80] and a
arge IBMTR analysis, maternal stem cell donation
as found to be better for HSCT than paternal do-
ation in mismatched transplantation. van Rood et al.
79], in their large IBMTR analysis, have shown that
he recipients of non-TCD maternal transplants had a
igniﬁcantly lower incidence of cGVHD than the re-
ipients of paternal transplants in haploidentical 1- or
-antigen-mismatched transplantations. They have
lso demonstrated a lower rate of aGVHD and TRM
n sibling transplantations mismatched for noninher-
ted maternal antigens (NIMAs) compared with those
ismatched for noninherited paternal antigens
NIPAs). Separate studies from Japan have conﬁrmed
he tolerizing effect of NIMAs after myeloablative
78,82] and RIC [83,84]. Although no differences in
isk of clinically signiﬁcant aGVHD were noted in
ne study, 5-year overall survival was signiﬁcantly
igher and TRM was lower among recipients of ma- pernal grafts compared to paternal grafts. In other
tudies, signiﬁcantly lower risks of GVHD were ob-
erved among NIMA-mismatched transplant recipi-
nts [84]. NIMA-mismatched sibling donor and recip-
ent share the inherited paternal antigens (IPAs) and
re mismatched at the maternal antigens, but there are
icrochimeric cells expressing the NIMAs. These ob-
ervations support the hypothesis that offspring may
e tolerant to haploidentical relatives expressing
IMAs (mother or NIMA-mismatched siblings), and
he microchimeric mother may be hyporesponsive to
PAs of the offspring. These encouraging results re-
orted so far provide rationale to assess the feasibility
f haploidentical stem cell transplant (SCT) using
ither myeloablative or nonmyeloablative condition-
ng regimen, from mother to offspring and vice versa,
r from NIMA-mismatched siblings. The approach
ay provide a more appropriate donor selection in
LA-haploidentical HSCT resulting in both less tox-
city and better antitumor effect.
ffects of Donor Lymphocyte Infusion on
utcome of Haploidentical Transplant
Although there has been a modest trend to reduce
RM in the past few years, there has been no clear
eduction in disease relapse, which still surpasses 50%
n high-risk patients [28,43]. The risk of day-100
RM has been reduced to below 20% in several
ecent series of haploidentical transplant using re-
uced-intensity conditioning protocols [67,58,64].
he high relapse rate observed in most series, apart
rom the inclusion of high proportion of high-risk
atients or patients with refractory diseases at the time
f transplant, is attributable to the delayed immune
ecovery and abrogated GVL effect with the use of
CD graft. Intensiﬁcation of conditioning regimens
s unlikely to compensate for the loss of T cell-related
VL effect, as the beneﬁt usually is offset with the
ncrease the regimen-related toxicity. Additional post-
ransplant strategies such as donor lymphocyte infu-
ion are potential therapeutic option for relapse pre-
ention.
Donor lymphocyte infusions (DLI) provides di-
ect and potent GVL activity to treat relapse in pa-
ients who have undergone HLA-matched, related, or
nrelated HSCT [85,86]. Reports on the use of un-
anipulated DLI in haploidentical transplant, both
rophylactically and therapeutically, remain scanty
29,38,39,87-91]. The diverse results reported in
erms of efﬁcacy, adverse events, and survival outcome
s more a reﬂection of the heterogeneity of patients
eing treated using this therapeutic strategy. In addi-
ion, given the limited number of patients in most of
hese reports, it is difﬁcult to draw deﬁnite conclu-
ions about the relationship between cell dose given,
VHD, and GVL effects. Nevertheless, several im-
ortant observations were made: (1) GVHD remains
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Haploidentical or Mismatched Transplant 1261n important risk after DLI, which can be a severe
omplication leading to death. (2) DLI is signiﬁcantly
ore effective when it is given during an early stage of
elapse when the disease burden is minimal [90,91].
To minimize the risk for GVHD, modiﬁed strat-
gies have been developed such as partially T cell-
epleted DLI [92]. In haploidentical SCT, studies
ave been initiated in which puriﬁed donor NK cells
ave been used in DLI with the aim to facilitate
ngraftment and induce GVT effects [93,94]. Al-
hough no ﬁrm conclusions can be made regarding the
linical efﬁcacy of NK-cell-based DLI at this stage,
he available data indicate that NK-cell infusions are
afe and can generate antitumor responses and long-
erm remission in some patients after leukemia re-
apse. The development of NK-cell-based DLI pre-
ents new possibilities to treat patients with tumor
elapse after haploidentical or cord-blood SCT in
hich T cell-based DLIs are not feasible.
elective TCD
With rigorous T cell depletion necessary to pre-
ent GVHD in the haploidentical setting that re-
ults in profound posttransplant immunodeﬁciency
95,96], a high morbidity/mortality from viral in-
ections because of the loss of antiviral immunity
nd high relapse rates as a result of the loss of the
VL response is not unanticipated. One of the
ost promising approaches to circumvent this dif-
culty involves selectively remove the T cells re-
ponsible for mediating GVHD, while conserving
VL and antimicrobial immune responses. This
an be accomplished by deleting T cells that be-
ome activated in response to recipient APC. In
everal murine transplant models, it has been shown
hat GVHD can be reduced or prevented by re-
oval or inactivation of alloreactive donor T cells
sing anti-CD25 [97,98], anti-CD69 [99], anti-
D95 [100], or photodepletion [101]. This prom-
sing approach has been tested by a number of
linical trials involving both HLA matched-sibling
onor and haploidentical donor transplantations,
nd the results suggest that the concept is feasible
97,102-104]. Amrolia et al. [104] recently reported
he results from a dose-escalation study using al-
odepleted T cells following haploidentical trans-
lantation in 16 patients with a median age of 9
ears (range: 2-58), treated mostly for high-risk
ematologic malignancies. Each patient was sched-
led to receive three infusions of allodepleted donor
cells on days 30, 60, and 90 after HSCT. Eight
atients received dose level 1 (104 cells/kg/dose)
nd 8 patients received dose levels 105 cells/kg/
ose. Only 2 patients developed signiﬁcant
GVHD, followed by extensive, cGVHD, with
eath in 1 of those patients from liver failure asso- oiated with GVHD and adenovirus. Patients at dose
evel 1 had T cell reconstitution consistent with
ther patients undergoing haploidentical HSCT
ithout allodepleted T cell add back. However,
atients at dose level 2 (105 cells/kg/dose) showed
igniﬁcantly improved T cell recovery time, partic-
larly at 3-5 months after HSCT, which is most
ften the time period in which patients die of in-
ection following haploidentical HSCT. Although
his selective allodepletion approach represents an
mportant step toward the goal of engineering stem
ell transplants to rapidly reconstitute immunity
ithout causing GVHD, several concerns and lim-
tations remain to be addressed before it can be
ore widely applied. (1) First, selective depletion
echniques are cumbersome and expensive in time
nd materials. Improved and simpler techniques will
e needed before the approach is universally appli-
able in routine transplant centers. (2) Second, the
est technique to eliminate alloreactive T cells re-
ains to be determined. There is a continuous need
o tailor the selective depletion technique for dif-
erent transplant situations, in particular, whether
he transplant is between HLA-matched related do-
or-recipient pairs or between unrelated or mis-
atched pairs, and whether the transplant is for
alignant or nonmalignant disease. (3) Third, there
s currently no generally accepted technique to de-
ermine whether a selective allodepleted product
ill be free of signiﬁcant GVHD risk. The corre-
ation between the clinical results (predicting the
isk of GVHD) and the in vitro tests available such
s mixed lymphocyte reaction (MLR) and helper
-lymphocyte precursor (HTLp) need to be vali-
ated with more clinical studies. (4) The optimal
umber of T cells, including the allowable number
f residual alloreactive T cells, to include in the
raft remains unknown, and may vary among do-
or-recipient pairs. (5) Last, it is important to note
hat not all data obtained in murine or other animal
odels can be extrapolated to the clinic. The pre-
iminary clinical reported so far requires further
alidation in a large patient cohort to better deﬁne
he optimal strategies for each situation.
ow to Choose Among Options? Which
lternative Donors and Which
onditioning Regimens?
For patients requiring an allograft but do not have
LA-identical sibling, the decision on the choice of
est alternative source of stem cells remains difﬁcult
nd controversial. In the absence of randomized stud-
es comparing the outcome of matched unrelated do-
or (MUD), unrelated umbilical cord blood (UD-
CB), and haploidentical transplants, we would not
ave robust evidence in guiding us with which to carry
ut this decision-making process.
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L.-P. KOH et al.1262In selecting the best alternative donor and type of
onditioning regimen and, one needs to take into
onsideration many parameters including age, perfor-
ance status, HLA risk factors, patient ethnicity, rar-
ty of HLA type, disease status, and urgency of the
ransplant. Other factors such as ﬁnancial status, avail-
bility of resource, and experience of transplant team
re important consideration also.
Which Alternative Donors? It has been well estab-
ished that patients with advanced leukemia are at
ncreased risk of transplantation failure [105]. Similar
o the matched unrelated transplant setting, clinical
tudies in mismatched transplants have documented
he importance of disease status in determining OS
38,33,43]. However, results from previous studies
uggest that the probability of long-term survival after
aploidentical transplant, based on disease-risk cate-
ory, are comparable to results after either unrelated
ransplant [8,19,20] or unrelated UCB transplant
106,107]. Drobyski et al. [30] have shown previously
hat the outcome of patients allografted from well-
atched unrelated donors was superior to those trans-
lanted from HLA-mismatched relatives or mis-
atched unrelated donors. The result is in contrast
ith the report by Lang et al., who observed superior
utcome after transplantation of large doses of blood-
erived CD34 cells from haploidentical-related do-
ors compared to matched unrelated donors. Taken
ogether, these reports suggest that for patients with
ess than perfectly matched unrelated donors, partially
atched-related donor may be an option if an allo-
raft is essential.
HLA mismatching and the associated increased
isks of graft failure, GVHD, and delayed immune
econstitution has tempered the enthusiasm of trans-
lant physicians from using mismatched donor for
ransplant. However, HLA mismatching is also asso-
iated with lower risk of disease recurrence. The out-
ome after haploidentical related and unrelated donor
ransplantation can be optimized through more com-
lete and precise HLA matching of the donor and
ecipient, and through NK-mediated KIR effects. The
tudies by IBMTR and the Japanese Society of He-
atopoeitic Cell Transplantation have shown that the
mpact of HLA mismatch on survival was smaller in
atients with high-risk disease a compared to stan-
ard-risk disease. The results has reinforced the
oint that the increased risk of aGVHD is counter-
alanced by a decrease in relapse in patients with
igh-risk disease, whereas the increased risk of
RM did not balance the change in the relapse rate
n standard-risk patients, in whom the risk of re-
apse is low. Clinical experience in Perugia and
uebingen has demonstrated that the outcome of
aploidentical transplant depends more on the dis-
ase status at transplant and patient’s history than
n HLA-incompatibility [38,43]. Also, 1 of the les- (ons learned from the Perugia series is that the
hoice of a KIR-ligand mismatched donor may be
eeded for successful results in haploidentical trans-
lant, particularly in patients with AML who are
ransplanted in remission. Another factor consid-
red to be critical in the decision of the choice of
lternative donors is the timing of transplant in
elation to the patient’s clinical course and the po-
ential loss of the optimal moment for transplanta-
ion due to delays in identifying a suitable donor.
revious studies have demonstrated that when a HLA
uitably matched stem cell source cannot be identiﬁed
mong current donor pools, HLA-haploidentical rel-
tives among family members may allow transplanta-
ion without delay [19,28,33].
On the basis of above arguments, a transplant
rom a haploidentical donor is perfectly acceptable,
nd may even be the preferred option in specialized
enters, especially under the following circumstances:
1) patient and donor are both CMV-negative; (2)
here is KIR mismatch between patient and donor; (3)
here is urgency for early transplant (such as patients
ith acute leukemia), and no matched donor can be
ound within a reasonable time frame.
Transplantation using unrelated UCB has re-
ently been explored in an increasing number of adult
atients, and been added to the list of options of
lternative source of stem cells for patients who do not
ave matched-related donors [11,12,108]. The relative
ase of procurement and the lower than anticipated
isk of severe aGVHD has made UCB transplantation
n appealing alternative to bone marrow-derived he-
atopoietic stem cells. UCB contained a sufﬁcient
umber of HSC to achieve engraftment in adult pa-
ients with lower than anticipated risk of severe
GVHD, even when HLA- disparate grafts are in-
used. The main obstacles in adults have been the risk
f graft failure and high TRM because of delayed
ematopoietic recovery. Although the data from the 2
arge registry-based studies has suggested lower rate
f aGVHD and comparable survival between unre-
ated marrow and UCB transplant in adults with acute
eukemia [109,110], there is currently still a lack of
ata comparing the outcome of patients receiving
aploidentical and UCB transplant. The question of
hoosing between UCB with a large number of nu-
leated cells versus mismatched-related transplanta-
ion is not an easy one to answer. Based on the avail-
ble data, one may prefer UCB to haploidentical or
artially matched donor in view of the lower aGVHD
bserved in UCB transplant recipients without any
pparent increase in relapse rate. However, the con-
ern with graft failure in an adult setting and delayed
mmune reconstitution remains. There are additional
isadvantages of UCB that make it less preferable
ompared to haploidentical donor, and these include:
1) the limitation of cell dose of UCB (even with 2
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Haploidentical or Mismatched Transplant 1263nits), which has profound inﬂuence on engraftment,
urvival, and TRM in the adult setting; (2) the logistic
roblem in donor recall, making donor lymphocyte
nfusion in the event of relapse almost impossible. In
ontrast, the problem of cell dose is less of a concern
n haploidentical transplant with the use of G-CSF-
obilized PBSC. Using mismatched family donors
lso provide continuous access to facilitate developing
onor-derived immunotherapy directed against in-
ection and/or underlying disease. Several small stud-
es have shown the feasibility of donor lymphocyte
nfusion in patients receiving haploidentical trans-
lant, given both prophylatically and therapeutically
88,90,91]. As the experience with the use of DL1 in
his setting remains limited, more studies are needed
efore this strategy can be offered to more haploiden-
ical transplant recipients with high risk of relapse.
Fundamentally, the ultimate decision on the
hoice of best alternative donors rests with the unique
ractice experience of any transplant center. Centers
hat are experienced in cord blood transplant may be
illing to accept greater major HLA disparity, pro-
ided the graft contains an adequate cell dose. An
cceptance of greater major HLA disparity will also be
ound in centers with well-established experience us-
ng haploidentical-related donors. The ability to man-
ge mismatch for multiple major HLA disparity re-
uires both clinical expertise and well-established
linical protocols.
Which Conditioning Regimen? The age and perfor-
ance status of the patients are important consider-
tion before deciding on the choice of conditioning
egimen. It is well established that most full ablative
egimens used in haploidentical transplant are associ-
ted with more regimen-related toxicity and higher
arly TRM, and thus not suitable for older and med-
cally inﬁrm patients. The high TRM reported in
ost the of studies of haploidentical transplant is
ttributed partly to the toxicity of the intensive con-
itioning regimen, as well as the inclusion of patients
ho are inherently at higher risk for infection and
oxicity death because of aggressively managed refrac-
ory disease. Nonmyeloablative or RIC, in this regard,
ffers the beneﬁt of lower toxicity with high rate of
ngraftment, and has thus extended the applicability
f allogeneic transplant to almost all patients. Our
roup and others have shown favorable outcome with
ow TRM among patients receiving nonmyeloablative
aploidentical transplantation [36,56,65]. In our se-
ies, which consisted mainly of patients with high-risk
isease, the 31% 1-year OS with a median 4.25-year
ollow-up time compares favorably with other ablative
aploidentical (28% survival rate with median fol-
ow-up of 18 months) or cord blood transplantation
28% survival rate with median follow-up of 22
onths). Importantly, in the subgroup of standard risk
atients, the 63% 1-year median survival rate and 2.9- iear median survival time are very encouraging and
ompare quite favorably with reports using alternative
atched unrelated donors or cord blood [61,111-113].
his encouraging result demonstrates the feasibility of
sing haploidentical family donors for nonmyeloblative
llogeneic transplantation in older, more inﬁrm patients,
roviding a readily available donor for all patients who
re considering allogeneic therapy. It has also high-
ighted that the indications for nonmyeloablative versus
yeloablative preparative regimen need to be carefully
eﬁned. The beneﬁt of reduced toxicity with nonmy-
loablative regimens may be offset by the loss of cytore-
uction-induced by high-dose chemotherapy, giving rise
o higher risk of relapse in patients with refractory
isease.
In summary, prospective randomized trials com-
aring haploidentical donor, matched unrelated do-
or, and cord blood transplant are needed to deter-
ine whether there is a preference among available
lternative donor sources. However, as most hap-
oidentical transplants are performed in situations
here the options of matched related or unrelated
onor transplant are not available, no prospective ran-
omized studies comparing the different alternative
onors would be, or likely to be, to be performed in
he near future. In the absence of differences, prag-
atic and logistic issues surface, those being primarily
ost and time. In this respect, the use of a haploiden-
ical donor confers the advantage of immediate donor
vailability and reducing costs associated with obtain-
ng the graft, including substantial federal and private
unding required to develop and maintain donor reg-
stries and banks. The timing of transplant, preferably
hen patients are in remission, is the one factor most
ikely to improve long-term outcome. The ability to
se haploidentical family donors provides near-unre-
tricted access to allogeneic stem cell therapy.
ONCLUSIONS
Haploidentical HSCT provides an opportunity
or patients to beneﬁt from HSCT when a 6 of 6 HLA
enotypically matched sibling is not available. It pre-
ents an easier logistic and practical alternative to
atched unrelated donor transplantation as well. This
ay be especially important when dealing with a pa-
ient suffering from a disease with a rapid tempo and
lso for non-Caucasian patients, in whom the chances
f ﬁnding an available matched unrelated match are
till low. Recent advances with effective TCD and
IC have signiﬁcantly decreased the early TRM and
isk of severe GVHD, whereas enabling reliable en-
raftment, and hence enhancing the therapeutic ben-
ﬁts of haploidentical transplantation. However, post-
ransplant infectious complications and relapse remain
mportant barriers to overcome. New directions in the
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L.-P. KOH et al.1264se of adoptive cellular immunity appear promising.
reliminary data has demonstrated the great potential
f selective allodepletion in rapidly reconstituting im-
unity without GVHD. It appears that in some TCD
aploidentical transplants, the beneﬁt of NK alloreac-
ivity is expected to encourage the greater use of
aploidentical transplants for a larger number of leu-
emia patients without matched donors. In addition,
here are emerging data to suggest the use of NIMA-
ismatched donors in providing an especially attrac-
ive strategy for patients to further minimize the risk
f GVHD. There are many issues that remain unre-
olved, including the role in certain diseases and tim-
ng of haploidentical HSCT. The relative merits of a
aploidentical family donor versus mismatched unre-
ated or umbilical cord blood donor remain to be
eﬁned. The data presented to date provides an impor-
ant framework for future improvements via more ap-
ropriate patient selection, better donor selection, devel-
pment of conditioning regimens that are safer yet result
n reliable engraftment, andmore effective strategies that
liminate the high risk of severe GVHD, whereas pre-
erving antitumor and antimicrobial immunocompe-
ence.
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